Skip to main
RXST

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 0%
Hold 67%
Sell 22%
Strong Sell 0%

Bulls say

RxSight Inc. reported operating expenses of $36.4 million, reflecting an increase of $2.0 million year-over-year, while its revenue for the third quarter exceeded consensus expectations and prompted management to raise the mid-point of its guidance. The company anticipates gross margins for 2025 to be between 76-77%, an increase from previous guidance, indicating potential for improved profitability. Additionally, favorable factors such as an accelerated installed base growth of light adjustable lenses (LDD), enhanced utilization, increased volumes of light adjustable lenses (LAL), and overall margin improvement could serve as significant catalysts for RxSight's financial performance moving forward.

Bears say

RxSight Inc. is experiencing a decline in key performance metrics, with monthly utilization of light adjustable lenses (LALs) dropping to 8.0 per lens delivery device (LDD) in 3Q25, down from 8.7 in 2Q25 and 10.1 in 3Q24. The company has revised its fiscal year 2026 revenue guidance to $120-135 million, indicating a potential revenue decline of up to 11% year-over-year, which falls short of both internal and market expectations. Additionally, RxSight is facing increased pressures on gross margins due to higher-cost inventory, which is projected to lead to sequential revenue contraction into 2026.

RxSight (RXST) has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 9 analysts, RxSight (RXST) has a Hold consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.